Notes
2016 euros
Reference
Soini E, et al. Cost-Utility of First-Line Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis. Clinical Therapeutics : 13 Feb 2017. Available from: URL: http://doi.org/10.1016/j.clinthera.2017.01.028
Rights and permissions
About this article
Cite this article
Teriflunomide cost effective for RRMS in Finland. PharmacoEcon Outcomes News 773, 34 (2017). https://doi.org/10.1007/s40274-017-3819-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3819-9